Abstract
The goal of the study was to examine the reasons given by parents who accepted or refused the HPV vaccine for their daughters in the context of a free provincial school-based vaccination program. A random sample of parents of 9–10 y old girls completed a mail-in questionnaire. Parents’ responses to 2 open-ended questions were assessed using content analysis. Coding themes were derived from the Health Belief Model. 806 parents returned and answered the relevant items. 88% of these parents decided to vaccinate their daughter. The primary reasons for parents’ acceptance was the perceived benefits (e.g., health protection, cancer/HPV prevention) and cues to action (e.g., physician recommendation, trusting the school vaccine program). Reasons for parental refusal included barriers (e.g., fear of side effects) and low susceptibility (e.g., their daughter is not at risk). Both groups of parents had unanswered questions, doubts and often inaccurate information. This study provides unique insight into parents’ perspectives concerning the decision making process for their daughter. There appears to be a need for accurate and complete information to assure informed HPV vaccine decision-making by parents and to increase HPV vaccine uptake.
Introduction
The Human Papillomavirus (HPV) is the most common sexually transmitted infection (STI) in the world, infecting 3 out of 4 people at least once in their lives.Citation1 There are over 120 different strains of the virus and although most HPV infections clear up on their own, persistent infections can lead to life-threatening consequences. Certain types of HPV are oncogenic in that they are cancer causing. There is now substantial evidence showing that HPV can be detected in virtually all cases of cervical cancer.Citation2,3 HPV is also associated with other types of cancers including vulvar, vaginal, penile, anal, and oropharyngeal (head and neck) cancers.Citation4,5 Additionally, 2 non-oncogenic types of HPV are responsible for a significant proportion of genital warts.Citation6,7
Due to the burden of HPV-related disease, 2 vaccines have been developed and approved for use, namely Gardasil® (Merck) and Cervarix® (GlaxoSmithKline). These vaccines have been evaluated in extensive randomized controlled trials and are nearly 100% effective in preventing new HPV infections (caused by the leading strains), and in turn have an efficacy of >90% in preventing cervical intraepithelial neoplasia (CIN2/3).Citation1,8 Because HPV is sexually transmitted, the vaccine has maximum benefit when given prior to initiation of sexual activity when immunogenicity is the strongest.Citation9,10 In Canada, vaccination is currently approved and recommended for females 9 to 45 y of age and for males 9 to 26 y of age.Citation11
In 2007, the Canadian government allocated $300 million to the provinces/territories for HPV immunization programs.Citation12 In September 2007, the provinces began introducing free school-based immunization programs for females in grades 5 to 8, and catch up immunization programs in grades 8 to 10 (grades vary by province).Citation1,13 However, universal school-based vaccination programs are presently only in place for young girls, with the exception of 2 Canadian provinces (Alberta and Prince Edward Island) who recently (April 2013) announced extensions of vaccination programs to include boys.Citation14 Because it is encouraged that Canadian children get vaccinated prior to the age of 13,Citation15 parental consent is critical in the vaccination process.
The development of the HPV vaccine has led to the emergence of a new era in cancer prevention. However, HPV vaccination programs for children have generated great controversy among the general public, including parents. The literature on parental HPV vaccine decision-making cites several barriers to vaccination including: a lack of research on the long term efficacy and side effects of the vaccine, the age of vaccination administration being too young, mistrust of pharmaceutical companies, and fears that the vaccine would promote early sexual activity and/or reduce self-protective sexual behaviors – also referred to as sexual disinhibition or risk compensation.Citation16-18 In addition, the cost of the HPV vaccine (which is approximately $450 CAD for 3 doses) has been reported as one of the principal barriers to vaccination.Citation19,20
Implementation of publicly funded HPV vaccination programs across Canada removes the barrier of cost, thus allowing unhindered exploration of other factors that impact parental attitudes and beliefs concerning vaccination.Citation21 Correspondingly, the purpose of the present study is to examine the reasoning underlying parents’ decisions to either accept or refuse HPV vaccination for their daughters within this provincial HPV vaccination program. Specifically, this study aims to understand parents’ subjective perceptions regarding the risks and benefits of vaccination, including the factors parents believe influenced their decision whether or not to vaccinate their daughters. In turn, this information can better guide public health policies as well as the development of educational interventions for parents making health decisions for their child.
Results
The sample was composed mostly of mothers (95.6% female) and the average age of participants was 40.2 y (SD = 5.36, range = 26–73). Most of the sample was married or in a common law relationship (80.2%) and there were on average 4.14 members (SD = 1.03, range = 2–8) in a given household. The majority of the sample spoke French as their first language (83.5%) and were born in Canada (90%). In terms of the socio-economic status of the sample, 82.7% were employed and slightly more than one third (36.6%) reported their annual household income to be less than $60,000. Detailed demographic and sample characteristics can be found in .
Table 1. Sample Characteristics (n = 806)
Of the 806 parents that provided qualitative responses, 708 (88%) parents accepted and 98 (12%) refused the vaccine for their daughters. A detailed listing of reasons associated with parental acceptance or refusal of the vaccine along with corresponding example quotes can be found in and . It is important to note that some parents gave more than one reason for their decision [in their open-ended answer]; therefore, there are more reasons cited than there are parents.
Table 2. Reasons given by parents who accepted vaccination (n = 708)
Table 3. Reasons given for parents who refused vaccination (n = 98)
Of those parents who accepted the vaccine for their daughters (see ), the majority (n = 499) cited benefits of vaccination as the reason for their decision. Benefits of HPV vaccination included: general health protection (n = 287), associating the vaccine with HPV or cancer prevention (n = 104 and n = 33, respectively), general positive attitudes toward vaccinations (n = 62), and the belief that the benefits of vaccination outweigh the risks of HPV (n = 17).
The second most common factor that influenced parents’ decisions was cues to action (n = 214). Specifically, cues to action included: trusting the school vaccination program and/or public health organizations (n = 71), receiving a doctor's recommendation (n = 60), parents’ personal experiences with HPV/abnormal pap tests (n = 29), being influenced by the media (n = 21), having a relative experience HPV or cancer (n = 17) and pressure to comply with social norms (e.g., other parents accepting the vaccine for their daughters; n = 10) were all important prompts governing the decision to accept the vaccine for their daughters.
An additional 15 parents consented to the HPV vaccine because they felt that their daughters might be susceptible to increased and/or earlier sexual activity. Seventeen parents made their decision based on anticipated regret. In other words, they accepted the vaccine because they feared they would otherwise feel regret if their daughter contracted an HPV infection in the future and they had refused the vaccine.
Parents who refused the vaccine for their daughters reported that their primary reasons for doing so were common barriers (n = 71, see ). Some of the more specific barriers reported were concerning vaccine protection. As an example, some parents had doubts about the safety of the vaccine (n = 14), the effectiveness of the vaccine (n = 10) and the duration of vaccine protection (n = 8). A few parents feared potential long-term side effects associated with the vaccine (n = 12) while a small minority (n = 2) questioned the actual severity of HPV or felt that their daughter should decide for herself (n = 3). Some parents reported being against vaccines in general (n = 5) while others reported not having enough information about the vaccine (n = 11) or were suspicious that pharmaceutical lobbying was behind HPV vaccine campaigns (n = 11).
The second most common factor related to vaccine refusal was susceptibility (n = 32) whereby parents felt that their daughters were not at risk for HPV. Specifically, some believed that the age of vaccination is too young/daughter is not yet sexually active (n = 25), or that their daughters were instilled with moral values surrounding abstinence/other modes of protection (n = 10). Cues to action were not generally cited as reasons for vaccine refusal. For example, only 4 parents reported that a doctor recommended against the vaccine. Similarly, only 3 parents acknowledged negative media attention (about the HPV vaccine) as being the source of their decision.
Among the 138 supplementary comments that were provided by the parents who accepted the vaccine, over 70% parents (n = 100) still had questions about HPV and the HPV vaccine. For example, some parents (n = 13) still had remaining doubts about vaccination safety, specifically with regards to the long-term efficacy or necessity of the vaccine (n = 8). Others were apprehensive about vaccinating their daughters at such an early age (n = 13) and some were uncomfortable with the pressure from vaccination campaigns (n = 9) to vaccinate their daughters. Furthermore, a very small subgroup of parents who accepted the vaccine later expressed regretting their decision (n = 6).
Discussion
In our sample, the majority of parents participating in the Quebec vaccination program reported accepting the vaccine for their daughters. The principal reason reported for acceptance was the perception that the vaccine would be beneficial for their daughters’ health. However, some parents who accepted the vaccine also expressed having remaining concern, lingering questions and/or regret. Providing appropriate and continuing education and resources to parents may help to increase confidence in decision-making. This approach may be critical to ensure completion of the vaccine regimen (2 dose regimen in grade 4 in Quebec, at the time of present study).
The HPV vaccine has been the subject of much controversy, mainly due to public fears that receiving the vaccine would encourage sexual promiscuity, elicit sexual activity at an earlier age, and/or reduce self-protective sexual behaviors. On the contrary, several studies have found no association between the HPV vaccine and sexual promiscuity.Citation18,20,Citation22-24 In fact, the vaccine has actually been shown to be associated with more responsible and safer sexual behaviors, such as condom use, regular Pap screening and STI testing.Citation25,26 In line with this, while the majority of parents in our sample who refused the vaccine reported several concerns regarding the effectiveness and safety of the vaccine, no parents reported concerns about the impact of vaccination on riskier or earlier sexual activity. This result highlights that claims made by some parents and/or the media suggesting that HPV vaccination will lead to risk compensation or younger sexual activity may be over exaggerated, and are not necessarily a legitimate post-vaccination concern among parents.Citation18,27,28 Importantly, some parents who accepted the vaccine did so based on the premise that earlier sexual activity is commonplace among today's generation, which suggests that (earlier) sexual activity was not a consequence of HPV vaccination, but rather a precursor. This issue warrants further investigation.
The HBM considers 5 distinct factors: perceived threat and severity of a disease, benefits and barriers (e.g., beliefs in the efficacy of the preventive measure) and cues to action. The results suggest that the potential benefits of vaccination were important for acceptors. This may suggest that the more finite points (e.g., how susceptible your daughter is to HPV) is less of an influential factor than general health protection and/or cancer prevention. For the refusers, the influencing factors were more varied and consisted of both barriers (e.g., questions about safety, duration of protection) and susceptibility (e.g., contrary to acceptors, these parents saw no need to vaccinate their daughters since they were not yet sexually active.)
Strengths and limitations
One important limitation to consider is that the overall response rate was relatively modest (33%). Despite this, our sample size was large for a qualitative study. Another limitation is that only a small proportion of our sample had refused the vaccine for their daughters, yielding only a modest amount of data for this group. Similarly, our sample was composed mostly of mothers, thus the perspectives of fathers are not represented. Notably, in our study, the proportion of parents who refused the HPV vaccine compared to those who accepted, as well as the ratio of mothers to fathers, is similar to the proportions reported in other studies of parental acceptance of the HPV vaccine.Citation17,29 In fact, many studies have acknowledged that mothers/female guardians are often the primary decision-makers when it comes to health-care decisions in the household,Citation30,31 and a large representation of females is typical in Quebec vaccine coverage studies.Citation32
An important limitation with open-ended questions is that respondents can only mention influences of which they are aware. Furthermore, respondents are more likely to verbalize salient or immediate influences, while leaving out those that are more distant and less conspicuous. As an example, although past compliance to other childhood vaccinations had an effect on their decision to vaccinate,Citation33 parents rarely mentioned this as a reason when asked open-endedly. This example supports the utility and value of a mixed methods design.
Lastly, it is important to note that many parents who accepted the HPV vaccine for their daughters consented to the initiation of the vaccine series, but may not have necessarily completed the 2-dose regimen at the time of the study. Accordingly, over the course of 5 y (first 2 doses administered in grade 4 and a booster dose first planned but finally not administered, based on a decision by the government of Quebec, in Grade 9), parents may be exposed to other factors in the interim that influence their initial and final decision. However, since there is now evidence to suggest that 2 doses of the HPV vaccine may be sufficient to bolster immunity,Citation34,35 the province of Quebec has opted to administer 2 doses.Citation15
Research implication and future directions
Future research directions should better address the informational needs of parents not only prior to vaccination, but also following vaccination since parents in our sample seemed to desire more information after having made their decision. This was true regardless of whether they accepted or refused the HPV vaccine for their daughters. Another important issue is that although parents are the ones deciding to vaccinate their children, young girls are the ones receiving the vaccination. The literature suggests that at the time of vaccination, many girls have not heard of HPV or the HPV vaccine and several may not even be aware that they have been vaccinated against HPV. For this reason, examining parent-daughter communication is another important area of research that will be crucial for understanding how information about sexual health is transmitted from the consenting party (the parent) to the recipient of the health behavior (a minor). Specifically, does the child even understand why she is receiving the vaccine (to prevent a sexually transmitted infection which causes genital warts and cancer)? Further, recipients of the HPV vaccine need to be made aware of certain health practices that should still be adopted despite being protected from certain strands of the HPV (e.g., regular Pap/HPV screening, safe sex practices including condom use, STI testing, etc.).
In summary, within the context of a school-based program, most Quebec parents accepted the vaccine for their daughter, citing general health benefits and/or cancer/HPV prevention as the most commonly reported reason. Cues to action such as a recommendation from a physician, a relative or from the child's school were also important reasons given for those who accepted. On the other hand, vaccine refusers cited barriers that can be conceptualized as a lack of or inadequate knowledge. This included fears about side effects, concerns about safety and vaccine efficacy/protection. Parents who refused also felt that their daughters were not susceptible or at risk to get HPV and/or that she was too young to receive the HPV vaccine. Interestingly, neither group of parents reported that giving the HPV vaccine would lead their daughter to have sex at an earlier age, or lead to increased and/or riskier sexual behaviors. In fact, some parents believed that “kids these days” are having sex at an earlier age and therefore wanted their daughters to be protected. The results of these qualitative analyses largely coincide with our quantitative findings,Citation33 therefore providing convergent validity. The parents’ comments provide both nuance and breadth, with rich details of their subjective perspective on decision-making; such details are often lost in a purely quantitative analysis.
Both groups of parents had remaining questions, doubts and often inaccurate information. Parents who refused the vaccine require supplementary information as well as clarification of misconceptions to adequately decide whether or not to vaccinate their daughters. Parents who accepted but expressed concerns or regret, require further education to guarantee completion of the vaccine regimen. Providing parents’ with information to address their reported lack of knowledge will help increase confidence in their decision for their daughter and perhaps their other children when they reach the appropriate age for HPV vaccination. This highlights the need to disseminate to parents information that is accurate, appropriate and sufficient.
The current findings can be used to help inform the development of and testing of interventions to allay the fears of parents who may refuse HPV vaccination as well as to reassure parents who agreed to vaccinate but still want more information and/or expressed some regret post-vaccination. With the evidence and/or development of new and existing vaccines that prevent other HPV-related cancers (including vulvar, vaginal, anal, penile and head and neck cancers), it is critical to ensure that the unique informational needs of parents are addressed in order to assure informed, educated decision-making regarding the HPV vaccine.
Methods
Using the Régie de l'assurance maladie du Québec database (Quebec's public health care system), Quebec parents of girls in grade 4, typically 9–10 y old, were randomly selected (n = 2500).Footnote Parents were mailed an invitation letter to participate in the study, a consent form, and a questionnaire composed of quantitative and qualitative questions. A modified Dillman's Total Design methodCitation36 was employed using a reminder post card at 1 week and replacement surveys at 4 weeks to maximize the response rate. Data were collected from January 25, 2010 to July 25, 2010. The study protocol was reviewed and approved by the Commission d’accès à l’information du Québec (CAIQ) and the McGill University Research Ethics Board.
The present article focuses on the qualitative component of the study where parents were asked to explain why they did or did not have their daughter vaccinated in an open-ended format. Parents were asked in either English or French: ‘In your own words, why did you decide to vaccinate or not vaccinate your daughter?’Footnote Parents were also invited to leave any additional comments with the following item: ‘If you have any additional comments that you would like to share, please feel welcome to do so below’. For both of these open ended items, respondents could fill up to 4 double spaced lines. The quantitative results are presented in a separate manuscript.Citation33
Eight-hundred and thirty four parents responded and returned the questionnaire. Eight hundred and six answered the open-ended questions and 138 entered additional comments. These responses were transcribed and analyzed using N’Vivo 10. A primary coding scheme was developed and discussed with the research team. The Health Belief Model (HBM) was selected by the authors as the theoretical framework through which to analyze parents’ responses. The HBM is a conceptual framework consisting of beliefs and attitudinal constructs that seek to explain the adoption of health behaviors (e.g., cancer screening, smoking).Citation37 It is a useful tool for understanding the role of factors that are thought to explain and predict the adoption of a specific health behavior (e.g., decision to vaccinate). The HBM has been used in numerous studies examining HPV vaccine decision-making.Citation38-40
Two frames were developed: one for the parents who accepted the vaccine and one for the parents who refused the vaccine. The HBM proposes that the likelihood that a certain health behavior will be adopted is influenced by 5 key constructs: perceived susceptibility to the disease, perceived severity of the disease, benefits and barriers of performing the behavior, and cues to action which is defined as any external source (e.g., doctor recommendation, media reports) that have the potential to instigate the behavior in question.Citation41
Content analysis is a method used to extract and reduce data from a body of qualitative material by systematically and objectively identifying specified characteristics of the material in order to better understand their meaning.Citation42,43 The present content analysis was performed using NVivo 10 software. All comments were read by 2 authors (ED, MV). Data codification was performed by MV. The data was then organized into themes, which were chosen a prior by the authors, based on the theoretical constructs of the HBM. Conceptual categories were then created and concepts belonging to a similar dimension were regrouped. On an iterative basis, these conceptual categories were updated and revised until saturation was achieved, in other words when no new properties, dimensions or relationships emerged during subsequent analysis. After coding a few of the comments, the coding tree was discussed by the authors (ED and MV) and adjusted. Ambiguous comments were discussed and consensus was achieved among the authors (ED, MV, SP and LG).
Disclosure of Potential Conflicts of Interest
Dr. Rosberger reports personal fees, outside the submitted work, as a consultant at a workshop on behavioral science issues for Merck in November 2012. All other authors declare no additional conflict of interest.
Acknowledgments
The authors would like to thank Eduardo Franco, Vladimir Gilca, Ellen Stephenson, Elsa Lau, Keven Joyal-Desmarais and Christopher Brown for their many important contributions to this project.
Funding
This study was funded by grant # 94479 from the Canadian Institutes of Health Research (CIHR) to Dr. Rosberger.
Notes
a A school HPV vaccination program for females enrolled in fourth grade, was established in the Quebec schools in 2007. The Quebec health care system gave us access to all parents who had a daughter aged 9–10 years old.
b In French, parents were asked “Dans vos propre mots, pourquoi avez-vous décidé de vacciner ou non votre fille?”
Related Research Data
References
- Shearer BD. HPV vaccination: Understanding the impact of HPV disease. Purple Paper: Natl Collaborating Centre Infect Dis 2011 [Internet]; 34: 1-18. Available from: www.nccid.ca/files/Purple_Paper_Note_mauve/PP_34_EN.pdf
- Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: population based prospective follow up study. BMJ 2002; 325:572-6; PMID:12228133; http://dx.doi.org/10.1136/bmj.325.7364.572
- Myers ER. The economic impact of HPV vaccines: not just cervical cancer. Am J Obstet Gynecol 2008; 198:487-8; PMID:18455522; http://dx.doi.org/10.1016/j.ajog.2008.03.056
- de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, Plummer M. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol 2012; 13:607-15; PMID:22575588; http://dx.doi.org/10.1016/S1470-2045(12)70137-7
- Muñoz N, Castellsague X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human cancer. Vaccine 2006; 24:S1-S10; PMID:16949995
- Patel H, Wagner M, Singhal P, Kothari S. Systematic review of the incidence and prevalence of genital warts. BMC Infect Dis 2013; 13:39; PMID:23347441; http://dx.doi.org/10.1186/1471-2334-13-39
- Cubie HA. Diseases associated with human papillomavirus infection. Virology 2013; 445:21-34; PMID:23932731; http://dx.doi.org/10.1016/j.virol.2013.06.007
- Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012; 30 Suppl 5:F123-38; PMID:23199956; http://dx.doi.org/10.1016/j.vaccine.2012.04.108
- Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet 2013; 382:889-99.
- National Advisory Committee on Immunization. Statement on human papillomavirus vaccine. Can Commun Dis Rep 2007 [Internet]; 33:1-32. Available from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/07vol33/acs-02/index-eng.php
- Canadian Immunization Committee. Recommendations for human papillomavirus immunization programs. Can. Commun. Dis. Rep. 2014 [Internet]; 40: 1-48. Available from: http://publications.gc.ca/site/eng/464264/publication.html
- Eggertson L. Provinces weighing HPV vaccination of boys. Can Med Assoc J 2012; 184:E250-1; PMID:22371513; http://dx.doi.org/10.1503/cmaj.109-4140
- National Advisory Committee on Immunization. Update on human papillomavirus (HPV) vaccines [Internet]. Can Commun Dis Rep, 2012; 38:1-62 [Internet]. Available from: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/12vol38/acs-dcc-1/index-eng.php
- The Society of Obstetricians and Gynaecologists of Canada. Alberta and PEI will include boys in HPV vaccination programs. Ottawa (Ontario): The Society of Obstetricians and Gynaecologists of Canada; 2013 [cited 2014 August 1]. Available from: http://sogc.org/news_items/alberta-and-pei-will-include-boys-in-hpv-vaccination-programs/
- Comité, Québec slid. HPV Immunization of Québec Pre-Adolescents: Two or Three Doses? In: Sauvageau C, Gilca V, eds. Quebec: Institut national de santé publique du Québec, 2013.
- Davis K, Dickman ED, Ferris D, Dias JK. Human papillomavirus vaccine acceptability among parents of 10- to 15-year-old adolescents. J Low Genit Tract Dis 2004; 8:188-94; PMID:15874862; http://dx.doi.org/10.1097/00128360-200407000-00005
- Walhart T. Parents, adolescents, children and the human papillomavirus vaccine: a review. Int Nurs Rev 2012; 59:305-11; PMID:22897180; http://dx.doi.org/10.1111/j.1466-7657.2012.00991.x
- Zimet GD, Rosberger Z, Fisher WA, Perez S, Stupiansky NW. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. Prev Med 2013; 57:414-8; PMID:23732252; http://dx.doi.org/10.1016/j.ypmed.2013.05.013
- Boehner CW, Howe SR, Bernstein DI, Rosenthal SL. Viral sexually transmitted disease vaccine acceptability among college students. Sex Transmitted Dis 2003; 30:774-8; PMID:14520177; http://dx.doi.org/10.1097/01.OLQ.0000078823.05041.9E
- Brewer NT, Fazekas KI. Predictors of HPV vaccine acceptability: a theory-informed, systematic review. Prev Med 2007; 45:107-14; PMID:17628649; http://dx.doi.org/10.1016/j.ypmed.2007.05.013
- Liau A, Stupiansky NW, Rosenthal SL, Zimet GD. Health beliefs and vaccine costs regarding human papillomavirus (HPV) vaccination among a U.S. national sample of adult women. Prev Med 2012; 54:277-9; PMID:22342703; http://dx.doi.org/10.1016/j.ypmed.2012.02.002
- Constantine NA, Jerman P. Acceptance of human papillomavirus vaccination among californian parents of daughters: a representative statewide analysis. J Adolesc Health 2007; 40:108-15; PMID:17259050; http://dx.doi.org/10.1016/j.jadohealth.2006.10.007
- Forster AS, Marlow LA, Stephenson J, Wardle J, Waller J. Human papillomavirus vaccination and sexual behaviour: cross-sectional and longitudinal surveys conducted in England. Vaccine 2012; 30:4939-44; PMID:22664223; http://dx.doi.org/10.1016/j.vaccine.2012.05.053
- Friedman AL, Shepeard H. Exploring the knowledge, attitudes, beliefs, and communication preferences of the general public regarding HPV. Health Educ Behav 2007; 34:471-85; PMID:17000622; http://dx.doi.org/10.1177/1090198106292022
- Kahn JA, Xu J, Zimet GD, Liu N, Gonin R, Dillard ME, Squires K. Risk perceptions after human papillomavirus vaccination in HIV-infected adolescents and young adult women. J Adolesc Health 2012; 50:464-70; PMID:22525109; http://dx.doi.org/10.1016/j.jadohealth.2011.09.005
- Mullins TL, Zimet GD, Rosenthal SL, Morrow C, Ding L, Shew M, Fortenberry JD, Bernstein DI, Kahn JA. Adolescent perceptions of risk and need for safer sexual behaviors after first human papillomavirus vaccination. Arch Pediatr Adolesc Med 2012; 166:82-8; PMID:22213755; http://dx.doi.org/10.1001/archpediatrics.2011.186
- Kwan TT, Tam KF, Lee PW, Lo SS, Chan KK, Ngan HY. De-stigmatising human papillomavirus in the context of cervical cancer: a randomised controlled trial. Psychooncology 2010; 19:1329-39; PMID:20186874; http://dx.doi.org/10.1002/pon.1706
- Forster A, Wardle J, Stephenson J, Waller J. Passport to promiscuity or lifesaver: press coverage of HPV vaccination and risky sexual behavior. J Health Commun 2010; 15:205-17; PMID:20390987; http://dx.doi.org/10.1080/10810730903528066
- Trim K, Nagji N, Elit L, Roy K. Parental knowledge, attitudes, and behaviours towards human papillomavirus vaccination for their children: A systematic review from 2001 to 2011. Obstet Gynecol Int 2012; 2012:921236; PMID:21977039; http://dx.doi.org/10.1155/2012/921236
- Comoro C, Nsimba SED, Warsame M, Tomson G. Local understanding, perceptions and reported practices of mothers/guardians and health workers on childhood malaria in a Tanzanian district—implications for malaria control. Acta Trop 2003; 87:305-13; PMID:12875923; http://dx.doi.org/10.1016/S0001-706X(03)00113-X
- Ray-Mazumder S. Role of gender, insurance status and culture in attitudes and health behavior in a US Chinese student population. Ethn Health 2001; 6:197-209; PMID:11696931; http://dx.doi.org/10.1080/13557850120078125
- Bouliane N BR, Audet D, Ouaki M. Enquête Sur la Couverture Vaccinale Des Enfants de 1 an et 2 Ans au Québec en 2012. Québec (Qc): Institut National de Sante Publique du Québec; 2013 January, 223p. Available from: http://www.inspq.qc.ca/pdf/publications/1651_EnquCouvVaccinEnfants1Et2Ans2012.pdf
- Krawczyk A, Knäuper B, Gilca V, Dubé E, Joyal-Desmarais K, Rosberger Z. Parents' decision-making about the human papillomavirus vaccine for their daughters: I. Quantitative results. Hum Vaccin Immunother 2015; 11:21-8.
- Romanowski B, Schwarz TF, Ferguson LM, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Catteau G, Dobbelaere K, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7:1374-86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
- Romanowski B, Schwarz TF, Ferguson LM, Ferguson M, Peters K, Dionne M, Schulze K, Ramjattan B, Hillemanns P, Behre U, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014; 10:1155-65; PMID:24576907; http://dx.doi.org/10.4161/hv.28022
- Dillman DA. Mail and Telephone Surveys: The Total Design Method. New York: Wiley & Sons, 1978.
- Champion VL, Skinner CS. The Health Belief Model. In: Glanz K, Rimer BK, Viswanath K, eds. Health Behavior and Health Education: Theory, Research, and Practice. San Francisco, CA: Jossey-Bass, 2008:45-65.
- Allen JD, Coronado GD, Williams RS, Glenn B, Escoffery C, Fernandez M, Tuff RA, Wilson KM, Mullen PD. A systematic review of measures used in studies of human papillomavirus (HPV) vaccine acceptability. Vaccine 2010; 28:4027-37; PMID:20412875; http://dx.doi.org/10.1016/j.vaccine.2010.03.063
- Krawczyk AL, Perez S, Lau E, Holcroft CA, Amsel R, Knauper B, Rosberger Z. Human papillomavirus vaccination intentions and uptake in college women. Health Psyc 2012; 31:685-93; PMID:22268713; http://dx.doi.org/10.1037/a0027012
- Perkins RB, Tipton H, Shu E, Marquez C, Belizaire M, Porter C, Clark JA, Pierre-Joseph N. Attitudes toward HPV vaccination among low-income and minority parents of sons: a qualitative analysis. Clin Pediatr (Phila) 2013; 52:231-40; PMID:23362316; http://dx.doi.org/10.1177/0009922812473775
- Glanz K, Rimer BK, Viswanath K. Health Behavior and Health Education: Theory, Research, and Practice. San Francisco, CA: Jossey-Bass, 2008.
- Patton MQPMQ. Qualitative Research & Evaluation Methods. Thousand Oaks, Calif; London: Sage, 2002.
- Smith CP. Content analysis and narrative analysis. In: Reis HTJCM, ed. Handbook of Research Methods in Social and Personality Psychology. New York: Cambridge University Press, 2000, 313-35.